Palleon Pharmaceuticals
MA - WalthamPharmaceutical
Focus: Palleon Pharmaceuticals is a public-stage company focused on glycoimmune checkpoint inhibitors, a novel immunotherapy modality targeting neurology indications. The company represents a specialized biotech focused on an emerging therapeutic approach.
Profile data last refreshed 22h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Palleon Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Palleon Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
E-602
OncologyClinical Trials (1)
NCT05259696Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Phase 1/2Help build intelligence for Palleon Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.